Sep 7, 2017   SOURCE: PR NewsWire

Sigilon Therapeutics to Present at Upcoming September Conferences

CAMBRIDGE, Mass., Sept. 7, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced the company will present at the following conferences in September.

24(th) Annual BioCentury NewsMakers in the Biotech Industry Conference

    Presenter:  Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy Officer and Head of
                Operations

    Date:      Friday, Sept. 8, 2017

    Time:      11 a.m. EDT

    Location:  Millennium Broadway Hotel, New York

GTCbio 4th Cell & Gene Therapy (CGT) Conference

    Title:      Next Generation Cell Therapies - Will These Revolutionize
                Healthcare?

    Presenter:  Devyn Smith, Ph.D., Sigilon Therapeutics Chief Strategy
                Officer and Head of Operations

    Date:      Monday, Sept. 11, 2017

    Time:      11:10 a.m. EDT

    Location:  Hyatt Regency Boston

15(th) Annual International Nanomedicine & Drug Delivery Symposium

    Title:                           Immune Modulatory Biomaterials for
                                     Cell-Based Therapies

    Presenter:                       Omid Veiseh, Ph.D., Sigilon
                                     Therapeutics Co-Founder

    Date:                           Saturday, Sept. 23, 2017

    Time:                           3 p.m. EDT

    Location:                        BSRB Kahn Auditorium, University
                                     of Michigan, Ann Arbor, Michigan

About Sigilon Therapeutics

Sigilon Therapeutics is developing treatments for chronic diseases using new biomaterials developed at the Massachusetts Institute of Technology that can shield implanted cells from immune attack. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as "protein factories" and responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.

For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.

View original content:http://www.prnewswire.com/news-releases/sigilon-therapeutics-to-present-at-upcoming-september-conferences-300515399.html

SOURCE Sigilon Therapeutics